7 results on '"Choudhary, Narendra S."'
Search Results
2. Good outcome of living donor liver transplantation for severe alcoholic hepatitis not responding to medical management: A single center experience of 39 patients.
- Author
-
Choudhary, Narendra S., Saigal, Sanjiv, Gautam, Dheeraj, Saraf, Neeraj, Rastogi, Amit, Goja, Sanjay, Bhangui, Prashant, Thiagrajan, Srinivasan, Yadav, Sanjay K., Mehrotra, Saurabh, Rastogi, Vipul, and Soin, Arvinder S.
- Subjects
- *
LIVER transplantation , *ALCOHOLIC liver diseases , *HEPATITIS , *ALCOHOL drinking , *MYCOSES - Abstract
Introduction: There are limited data on outcomes of living donor liver transplantation (LDLT) for patients with severe alcoholic hepatitis.Methods: The study included LDLT recipients for severe alcoholic hepatitis (n = 39) who did not improve with medical treatment and compared their outcomes with patients who underwent LDLT for alcoholic liver disease (n = 461). The diagnosis of severe alcoholic hepatitis was based on both clinical and explants data. No patients had psychiatric contraindications for liver transplant and all had good family support. The data are shown as number, mean (SD), or median (25-75 interquartile range).Results: All transplant recipients were males, aged 42 ± 8 years. The patients with alcoholic hepatitis were abstinent for a duration of 4 ± 1.8 months at the time of LDLT. All patients underwent LDLT with a graft to recipient weight ratio of 0.95 ± 0.17. The post-transplant ICU and hospital stay were 5.4 ± 1.3 and 17.6 ± 8.4 days, respectively. When patients with alcoholic hepatitis (n = 39) were compared to patients who underwent LDLT for alcoholic liver disease without alcoholic hepatitis (n = 461), patients with alcoholic hepatitis were significantly younger (43.2 ± 8.5 vs. 48.2 ± 9.1 years, p = 0.001) and had higher Child's (10.9 ± 1.5 vs. 9.8 ± 1.8) and MELD scores (22.1 ± 4.5 vs. 18.4 ± 5.9, p = 0.000). Post-operative infections were also significantly more common in the alcoholic hepatitis group (71.7% vs. 51.6%, p = 0.018). Fungal infections developed in 23% of alcoholic hepatitis patients as compared to 14% in the rest of the alcoholic patients (p = 0.247). Six recipients (15.7%) died at a median follow-up of 28 (6-37) months due to infections, and five (12.8%) patients had relapse of alcohol drinking. Survival was not different between the two groups.Conclusion: Living donor liver transplantation can be successfully performed with good survival for patients with severe alcoholic hepatitis. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
3. De Novo Autoimmune Hepatitis After Living Donor Liver Transplantation: A Series of 4 Cases.
- Author
-
Choudhary, Narendra S., Saigal, Sanjiv, Gautam, Dheeraj, Saraf, Neeraj, and Soin, Arvinder S.
- Subjects
- *
CHRONIC hepatitis C , *AUTOIMMUNE diseases , *LIVER transplantation , *IMMUNOGLOBULIN G , *INFLAMMATION - Abstract
While Autoimmune Hepatitis (AIH) may recur in patients after liver transplant, an AIH like presentation (positive auto antibodies, raised immunoglobulin G, raised transaminases and histology showing plasma cell rich infiltrate) may also occur in liver transplant recipients who had transplant for some other disease, called De novo Autoimmune Hepatitis (DAIH). A timely diagnosis and treatment can prevent further graft dysfunction. We report 4 cases of DAIH after living donor liver transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Outcome of Living Donor Liver Transplantation for Wilson's Disease in Adults: A Single Center Experience.
- Author
-
Choudhary, Narendra S., Saigal, Sanjiv, Saraf, Neeraj, Rastogi, Amit, Goja, Sanjay, Bhangui, Prashant, Thiagrajan, Srinivasan, Gautam, Dheeraj, Govil, Deepak, Vohra, Vijay, and Soin, Arvinder S.
- Subjects
- *
KIDNEY transplantation , *HEPATOLENTICULAR degeneration , *KIDNEY exchange , *CIRRHOSIS of the liver , *STEROIDS - Abstract
Introduction Although liver transplantation is a definitive cure for Wilson's disease (WD), there is limited data about results of living donor liver transplantation (LDLT) in adults. Material and methods 18 adults underwent LDLT for WD. The presentations before LDLT were decompensated cirrhosis ( n = 16), acute on chronic liver failure ( n = 1) and acute liver failure ( n = 1). The donors were parents ( n = 2), siblings ( n = 3), cousin ( n = 1), daughter ( n = 1), nephew ( n = 1), spouse or relatives of spouse ( n = 9) and from swap transplantation ( n = 1). All genetically related donors were negative for screening of WD. Results The study cohort comprised of 15 males and 3 females, aged 32 ± 10 years. Severity of liver disease (excluding acute liver failure patient) was as follows; Child's score 10 ± 2, model for end-stage liver disease (MELD) score 18 ± 6. The graft to recipient weight ratio was 1 ± 0.2. The ICU and hospital stay were 5.5 ± 0.9 and 15 ± 5 days. Two patients died in first month after liver transplantation, rest of patients are doing well at median 15 (8–38 months). Two patients had acute cellular rejection that responded to steroids, one had hepatic artery thrombosis and 2 had biliary strictures. Three patients had neurological symptoms; 2 of these patients had partial recovery while one had complete recovery. There was no significant difference between LDLT from genetically related or unrelated donors. Conclusion LDLT for WD in adults is associated with good outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of Hepatitis C Recurrence After Living Donor Liver Transplantation: An Experience From India.
- Author
-
Choudhary, Narendra S., Saigal, Sanjiv, Gautam, Dheeraj, Saraf, Neeraj, Rastogi, Amit, Goja, Sanjay, Bhangui, Prashant, and Soin, Arvinder S.
- Subjects
- *
HEPATITIS C treatment , *LIVER transplantation , *DRUG efficacy , *MEDICATION safety ,SOFOSBUVIR - Abstract
Introduction Results of Sofosbuvir based regimens for hepatitis C (HCV) recurrence after liver transplantation are available from well-designed clinical trials. Most of the data is from deceased donor liver transplant (DDLT) setting, and data on “real world” experience for HCV recurrence after living donor liver transplantation (LDLT) is limited. Material and methods Consecutive 78 patients who completed Sofosbuvir based HCV treatment after liver transplantation were included. Following Sofosbuvir based regimens were used; Sofosbuvir + Ribavirin ( n = 58), Sofosbuvir + Ledipasvir ± Ribavirin ( n = 5), Sofosbuvir + Daclatasvir ± Ribavirin ( n = 15). Treatment was given for 12 weeks (triple therapy) or 24 weeks (dual therapy). Results A total of 74/78 (94.8%) patients achieved end of treatment response (ETR) while 4 did not achieve ETR. A total of 68/76 (89.4%) patients achieved sustained virological response at 12 weeks (SVR12). while 2 are waiting for 12 weeks follow up after ETR. Twelve patients had history of failed previous treatment with Peginterferon and Ribavirin after LDLT, all these patients achieved ETR and 11/12 had SVR12. There was no statistical difference in response rates between genotype 1 or 3. Eighteen patients (16 on Ribavirin) had hemoglobin < 8 g/dl; two patients complained fatigue in absence of anemia. Conclusion Sofosbuvir based regimens are safe and highly effective in treatment of HCV recurrence after LDLT. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Liver Transplantation for Acute on Chronic Liver Failure.
- Author
-
Choudhary, Narendra S., Saraf, Neeraj, Saigal, Sanjiv, and Soin, Arvinder S.
- Subjects
- *
LIVER transplantation , *LIVER diseases , *LIVER failure , *CIRRHOSIS of the liver , *PROGNOSIS , *PATIENTS - Abstract
Background Acute-on chronic liver failure (ACLF) is defined as acute insult on previous liver disease that causes sudden worsening of liver functions. Methods ACLF is characterized by high incidence of organ failure and prognosis is remarkably worse than patients with cirrhosis. Incidence of organ failures is very high despite best medical care and timely liver transplant before development of multi organ failure is associated with good survival rates. Results At present, there are no reliable score or ways to correctly identify patients who are going to recover from patients who will need transplantation. Organ failures are important part of prognosis and to define need or futility of early liver transplantation. Conclusion Asian Pacific Association for the Study of the Liver (APASL) published their recommendations regarding ACLF in 2014. Several important studies regarding course/nature of disease and transplantation for ACLF became available after 2014 APASL recommendations and still there are some unanswered areas. The current review discusses various issues regarding liver transplantation in patients with ACLF. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Minimizing Incision in Living Donor Liver Transplantation: Initial Experience and Comparative Analysis of Upper Midline Incision in 115 Recipients.
- Author
-
Rastogi, Amit, Gupta, Ankur A., Bansal, Raghav, Valappil, Fysal Kollanta, Yadav, Kamal S., Chaudhary, Suchet, Bhangui, Prashant, Dhampalvar, Swapnil, Choudhary, Narendra S., Saraf, Neeraj, and Soin, Arvinder S.
- Subjects
- *
LIVER transplantation , *COMPARATIVE studies , *TREATMENT effectiveness , *PLEURAL effusions , *BOWEL obstructions , *CHOLANGIOGRAPHY , *KIDNEY transplantation - Abstract
Living donor liver transplantation (LDLT) needs "Mercedes Benz" or "J-shaped" incision, causing short and long-term complications. An upper midline incision (UMI) is less invasive alternative but technically challenging. Reporting UMI for recipients in LDLT vs. conventional J-shaped incision. Retrospective analysis, July 2021 to December 2022. Peri-operative details and post-transplant outcomes of 115 consecutive adult LDLT recipients transplanted with UMI compared with 140 recipients with J-shaped incision. Cohorts had similar preoperative and intraoperative variables. The UMI group had significant shorter time to ambulation (3 ± 1.6 vs. 3.6 ± 1.3 days, p = 0.001), ICU stay (3.8 ± 1.3 vs. 4.4 ± 1.5 days, p = 0.001), but a similar hospital stay (15.6±7.6 vs. 16.1±10.9 days, p = 0.677), lower incidence of pleural effusion (11.3% vs. 27.1% p = 0.002), and post-operative ileus (1.7% vs. 9.3% p = 0.011). The rates of graft dysfunction (4.3% vs. 8.5% p = 0.412), biliary complications (6.1% vs. 12.1% p = 0.099), 90-day mortality (7.8% vs. 12.1% p = 0.598) were similar. UMI-LDLT afforded benefits such as reduced pleuropulmonary complications, better early post-operative recovery and reduction in scar-related complaints in the medium-term. This is a safe, non-inferior and reproducible technique for LDLT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.